Literature DB >> 18539373

Induction therapy for elderly patients with acute myeloid leukemia.

Mike G Martin1, Camille N Abboud.   

Abstract

Acute myeloid leukemia (AML) is a disease of older adults. Efforts to intensify therapy along traditional avenues have failed to yield improved results. There remains significant clinical equipoise as to how to "induce" patients and whether or not 7+3-style regimens improve outcomes over low-dose cytarabine. What is certain is that even in those not receiving active therapy, AML is an exceptionally morbid disease. Diverse interventions are being explored in the management of older patients with AML and the currently available data will be reviewed.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18539373     DOI： 10.1016/j.blre.2008.04.004

Source DB:  PubMed          Journal:  Blood Rev        ISSN： 0268-960X            Impact factor:   8.250


  7 in total

1.  A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML.

Authors:  John S Welch; Haixia Niu; Geoffrey L Uy; Peter Westervelt; Camille N Abboud; Ravi Vij; Keith E Stockerl-Goldstein; Meagan Jacoby; Iskra Pusic; Mark A Schroeder; John F Dipersio; Amanda F Cashen
Journal:  Am J Hematol       Date:  2014-04-28       Impact factor: 10.047

2.  Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.

Authors:  Abhishek Maiti; Wei Qiao; Koji Sasaki; Farhad Ravandi; Tapan M Kadia; Elias J Jabbour; Naval G Daver; Gautam Borthakur; Guillermo Garcia-Manero; Sherry A Pierce; Kathryn S Montalbano; Naveen Pemmaraju; Kiran Naqvi; Maro Ohanian; Nicholas J Short; Yesid Alvarado; Koichi Takahashi; Musa Yilmaz; Nitin Jain; Steven M Kornblau; Michael Andreeff; Prithviraj Bose; Alessandra Ferrajoli; Ghayas C Issa; Lucia Masarova; Philip A Thompson; Caitlin R Rausch; Jing Ning; Hagop M Kantarjian; Courtney D DiNardo; Marina Y Konopleva
Journal:  Am J Hematol       Date:  2020-12-24       Impact factor: 10.047

3.  Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.

Authors:  Abhishek Maiti; Caitlin R Rausch; Jorge E Cortes; Naveen Pemmaraju; Naval G Daver; Farhad Ravandi; Guillermo Garcia-Manero; Gautam Borthakur; Kiran Naqvi; Maro Ohanian; Nicholas J Short; Yesid Alvarado; Tapan M Kadia; Koichi Takahashi; Musa Yilmaz; Nitin Jain; Steven Kornblau; Guillermo Montalban Bravo; Koji Sasaki; Michael Andreeff; Prithiviraj Bose; Alessandra Ferrajoli; Ghayas C Issa; Elias J Jabbour; Lucia Masarova; Philip A Thompson; Sa Wang; Sergej Konoplev; Sherry A Pierce; Jing Ning; Wei Qiao; John S Welch; Hagop M Kantarjian; Courtney D DiNardo; Marina Y Konopleva
Journal:  Haematologica       Date:  2021-03-01       Impact factor: 9.941

4.  Understanding and Targeting the Eukaryotic Translation Initiation Factor eIF4E in Head and Neck Cancer.

Authors:  Biljana Culjkovic; Katherine L Borden
Journal:  J Oncol       Date:  2009-12-13       Impact factor: 4.375

5.  The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML).

Authors:  Sarit Assouline; Eftihia Cocolakis; Katherine L B Borden
Journal:  Cancers (Basel)       Date:  2012-11-02       Impact factor: 6.639

6.  Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells.

Authors:  Peng Li; Sarah Diab; Mingfeng Yu; Julian Adams; Saiful Islam; Sunita K C Basnet; Hugo Albrecht; Robert Milne; Shudong Wang
Journal:  Oncotarget       Date:  2016-08-30

7.  Heteronemin, a marine natural product, sensitizes acute myeloid leukemia cells towards cytarabine chemotherapy by regulating farnesylation of Ras.

Authors:  Archana P Retnakumari; Shabna Anwar; Minakshi Saikia; Nikhil P Anto; Rashmi Mittal; Shabna Shah; Kavya S Pillai; Vinod S Balachandran; Vidya Peter; Reeba Thomas; Ruby John Anto
Journal:  Oncotarget       Date:  2018-04-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.